THERIVA BIOLOGICS INC

Theriva Biologics launches its first dose of VCN‑01 in the VIRAGE2 Phase 2a trial, aiming to boost safety and efficacy for metastatic pancreatic ductal adenocarcinoma treatment.

Theriva Biologics gets AEMPS clearance to launch VIRAGE2, a Phase IIa trial testing a higher‑dose oncolytic VCN‑01 combo for metastatic pancreatic cancer.

Theriva Biologics Inc. has reported unusual trading activity and filed for an at-the-market offering to raise up to $4 million to support the development of its adenovirus delivery platform.

Theriva Biologics Inc. has successfully closed a $7.5 million public offering to advance its pipeline of cancer therapies, following promising results from its VIRAGE Phase 2b clinical trial.